Ruxolitinib Reduces JAK2 p.V617F Allele Burden in Patients With Polycythemia Vera Enrolled in the RESPONSE Study

Collectively, the data from this exploratory analysis suggest that ruxolitinib treatment for up to 4 years provides progressive reductions in JAK2 p.V617F allele burden in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.

Ann Hematol